Analysis of HIV type 1 gp41 sequences in diverse HIV type 1 strains.
The HIV fusion inhibitor enfuvirtide (ENF/Fuzeon) targets the env gp41 transmembrane domain. Mutations in gp41 are associated with ENF resistance. We developed a prototype assay to genotype a 676-bp region spanning the heptad repeat domains (HR1 and HR2) of HIV-1 gp41. Plasma samples were collected from 126 HIV-1-infected blood donors in Cameroon, Brazil, Uganda, South Africa, Thailand, and Argentina. Based on analysis of gag p24, pol integrase, and env gp41 genes, the panel was composed of subtypes A/A2 (18), B (11), C (14), D (10), F/F2 (9), G (7), CRF01_AE (9), CRF02_AG (33), and recombinant strains (15). Genotyping was successful for 119 of the 126 samples (94.4%). Although numerous amino acid polymorphisms were detected in some samples, none had primary mutations associated with ENF resistance. The gp41 HIV-1 research reagents developed by Celera are useful tools for genotyping analysis of the gp41 region in diverse HIV-1 strains.
Eshleman
Susan H
SH
Johns Hopkins University, School of Medicine, Baltimore, Maryland 21205, USA. seshlem@jhmi.edu
Hudelson
Sarah E
SE
Bruce
Robert
R
Lee
Travis
T
Owens
Michelle R
MR
Hackett
John
J
Swanson
Priscilla
P
Devare
Sushil G
SG
Marlowe
Natalia
N
D001483:Base Sequence; D024882:Drug Resistance, Viral; D000077560:Enfuvirtide; D005838:Genotype; D015700:HIV Envelope Protein gp41 / Q000737:chemistry / Q000235:genetics* / Q000494:pharmacology; D023581:HIV Fusion Inhibitors / Q000494:pharmacology; D015658:HIV Infections / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000494:pharmacology; D011110:Polymorphism, Genetic; D017434:Protein Structure, Tertiary; D016415:Sequence Alignment
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide